Germany’s second largest health insurer withdraws appeal with Federal Social Court, accepts prior ruling of exoskeletons as direct disability compensation
11 11월 2022 - 10:00PM
ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"),
today welcomed the decision by BARMER to accept the prior
ruling from the state court that exoskeletons are considered
as direct disability compensation and withdraw the pending case at
the federal level shortly before the hearing. This outcome means
that an eligible insured person with spinal cord injury (SCI) has a
legal basis for the supply of an exoskeleton as an orthopedic aid
for direct disability compensation in Germany, ReWalk’s largest
market for exoskeletons.
In the precedent ruling, the court determined
that an exoskeleton device directly compensates for the loss of
abilities for the spinal cord injured individual, such as the
ability to stand, walk, and ascend or descend stairs and curbs. The
definition of direct disability compensation applies to medical
aids which replace failed and impaired bodily functions to the
extent that the person using them is on par with people without
disabilities. In this context, the provision of an advanced
technical aid, such as an exoskeleton, can be provided to the
medically eligible insured individual, regardless of any other
medical aids that have previously been supplied.
“The successful conclusion of this legal dispute identifying the
exoskeleton as direct disability compensation changes the landscape
for the eligible paralyzed community,” stated Larry Jasinski, CEO
of ReWalk. “The German healthcare system has led the way in its
adoption of exoskeletons for spinal cord injured individuals. We
expect that this acceptance of the prior ruling will enable
medically eligible members of the SCI community to access
exoskeleton technology in a more efficient manner.”
“We anticipate that today’s events will have immense
significance for paraplegics in Germany. The precedent set by the
state court is enforceable and legally binding and will help ensure
that eligible individuals with spinal cord injuries have a legal
basis to obtain this technology,” said Professor Thomas Ratajczak,
legal representative for the plaintiff in this case.
The plaintiff, Lars Vinken, stated, “After seven years of
waiting to walk in an exoskeleton, I am excited that BARMER will
now provide me with a ReWalk. It is of great value to know that
other paraplegics will now have easier access to this technology.
To be supplied with an exoskeleton and be able to stand up and walk
again at any time opens new horizons for me.”
For more information on ReWalk Robotics and the ReWalk
exoskeleton, visit rewalk.com
About ReWalk Robotics Ltd.ReWalk Robotics Ltd.
develops, manufactures and markets wearable robotic exoskeletons
for individuals with lower limb disabilities as a result of SCI or
stroke. ReWalk’s mission is to fundamentally change the quality of
life for individuals with lower limb disability through the
creation and development of market leading robotic technologies.
Founded in 2001, ReWalk has headquarters in the U.S., Israel and
Germany. For more information on the ReWalk systems, please visit
rewalk.com
ReWalk® and ReStore® are registered trademarks of ReWalk
Robotics Ltd. in the United States and other jurisdictions.
Forward-Looking StatementsIn addition to
historical information, this press release contains forward-looking
statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995, Section 27A of
the U.S. Securities Act of 1933, as amended, and Section
21E of the U.S. Securities Exchange Act of 1934, as
amended. Such forward-looking statements may include projections
regarding ReWalk's future performance and other statements that are
not statements of historical fact and, in some cases, may be
identified by words like "anticipate," "assume," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "future," "will," "should,"
"would," "seek" and similar terms or phrases. The forward-looking
statements contained in this press release are based on
management's current expectations, which are subject to
uncertainty, risks and changes in circumstances that are difficult
to predict and many of which are outside of ReWalk's control.
Important factors that could cause ReWalk's actual results to
differ materially from those indicated in the forward-looking
statements are more fully discussed in ReWalk’s periodic filings
with the Securities and Exchange Commission (“SEC”),
including the risk factors described under the heading "Risk
Factors" in ReWalk's annual report on Form 10-K and 10-K/A for the
year ended December 31, 2021 filed with
the SEC and other documents subsequently filed with or
furnished to the SEC. Any forward-looking statement made in
this press release speaks only as of the date hereof. Factors or
events that could cause ReWalk's actual results to differ from the
statements contained herein may emerge from time to time, and it is
not possible for ReWalk to predict all of them. Except as required
by law, ReWalk undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
ReWalk Media Relations:John TomlinE: media@rewalk.comReWalk
Investor Contact:Almog AdarDirector of FinanceReWalk Robotics
Ltd.T: +972-4-9590130 E: investorrelations@rewalk.com
ReWalk Robotics (NASDAQ:RWLK)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
ReWalk Robotics (NASDAQ:RWLK)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025